Has Raja Fattaleh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $53,498 in general payments to Raja Fattaleh, MD across 2,026 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Raja Fattaleh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Raja Fattaleh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Raja Fattaleh, MD

Family Medicine · Putnam, CTNPI 1841283439

Payments from drug & device makers

$53,498in general payments, 2019–2025

Across 2,026 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Teva Pharmaceuticals USA, Inc.$9K
Lilly USA, LLC$7K
AstraZeneca$4K
AbbVie$4K
Amgen$2K
Novo Nordisk$2K
plus $25K from 54 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Teva Pharmaceuticals USA, Inc.	96	$9,269
Lilly USA, LLC	45	$7,154
AstraZeneca	171	$4,428
AbbVie(2 entities)	246	$3,546
Amgen(2 entities)	88	$1,877
Novo Nordisk	102	$1,698
Boehringer Ingelheim	106	$1,675
Alkermes, Inc.	75	$1,668
Johnson & Johnson(2 entities)	78	$1,475
Pfizer	91	$1,450
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	78	$1,414
Sunovion Pharmaceuticals Inc.	51	$1,089
Otsuka America Pharmaceutical, Inc.	54	$1,001
Corcept Therapeutics	43	$997
Neurocrine Biosciences, Inc.	43	$983
GSK	53	$880
Jazz Pharmaceuticals Inc.	7	$698
Novartis	38	$667
Supernus Pharmaceuticals, Inc.	38	$649
Bayer	28	$634
Vanda Pharmaceuticals Inc.	23	$533
Axsome Therapeutics, Inc.	22	$511
Sanofi	15	$486
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	29	$463
Xeris Pharmaceuticals, Inc.	17	$406
Lundbeck LLC	18	$384
Phathom Pharmaceuticals, Inc.	20	$379
Merck	23	$371
Astellas Pharma US Inc	13	$369
Arbor Pharmaceuticals, Inc.	17	$364
Regeneron Healthcare Solutions, Inc.	16	$354
Eisai Inc.	24	$347
Harmony Biosciences LLC	15	$312
Sanofi-aventis U.S. LLC	15	$291
Corium, LLC	13	$258
Paratek Pharmaceuticals, Inc.	13	$249
Biodelivery Sciences International, Inc.	19	$245
Ardelyx, Inc.	8	$237
Takeda Pharmaceuticals U.S.A., Inc.	10	$193
Nestle Healthcare Nutrition Inc.	9	$188
Boston Scientific	2	$179
Radius Health, Inc.	8	$173
Actelion Pharmaceuticals US, Inc.	3	$165
Antares Pharma, Inc.	7	$158
Endo Pharmaceuticals Inc.	8	$157
Biohaven Pharmaceutical Holding Company Ltd.	7	$152
Azurity Pharmaceuticals, Inc.	8	$149
Exact Sciences	7	$148
E.r. Squibb & Sons, L.L.C.	7	$142
Esperion Therapeutics, Inc.	7	$141
Abbott	8	$139
Gilead	5	$123
Sumitomo Pharma America, Inc.	6	$115
Sobi, Inc	5	$109
Daiichi Sankyo Inc.	4	$74
Mylan Specialty L.p.	3	$69
Recordati_rare_diseases_inc.	3	$68
Evoke Pharma, Inc.	3	$60
Amarin Pharma, Inc.	3	$54
Biohaven Pharmaceuticals, Inc.	2	$53

How this compares

$53,498 in reported general payments places this provider in the 95th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut →

Medicare billing

Part B allowed, 2024

$291,844

Medicare patients

140

Services billed

15,879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Putnam

Debra GramlichStamford$292K
Hadrian HolderNew Haven$213K
Theodore BrunoDurham$201K
Kenneth DardickStorrs$146K
Raymond KurkerSouth Windsor$107K
Thao DoranMarlborough$102K
Nicholas TzikasNew Haven$46K
Andrew SelingerBristol$31K
Helar CamposNew London$29K
Kristin GianniniVernon$28K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →